arginyl-glycyl-aspartic acid has been researched along with melitten in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, DJ; Sun, Mn; Wang, Ys; Zhang, Sx; Zhu, Wh | 1 |
| Li, Y; Ma, J; Sun, D; Sun, M; Wang, Z; Zhu, W | 1 |
| Gao, J; Lu, W; Ren, Y; Wei, X; Xie, C; Yan, Z; Ying, M; Zhang, M | 1 |
3 other study(ies) available for arginyl-glycyl-aspartic acid and melitten
| Article | Year |
|---|---|
Expression and functional characterization of a recombinant targeted toxin with an uPA cleavable linker in Pichia pastoris.
Topics: Cell Line, Tumor; Chromatography, Gel; Cloning, Molecular; Crotalid Venoms; Disintegrins; Electrophoresis, Polyacrylamide Gel; Erythrocytes; Hemolysis; Humans; Melitten; Oligopeptides; Pichia; Recombinant Fusion Proteins; Urokinase-Type Plasminogen Activator | 2011 |
The anti-cancer potency and mechanism of a novel tumor-activated fused toxin, DLM.
Topics: Antineoplastic Agents; Blood Platelets; Cell Line, Tumor; Cell Survival; Disintegrins; Erythrocytes; Flow Cytometry; HEK293 Cells; Hemolysis; Humans; Melitten; Microscopy, Fluorescence; Oligopeptides; Platelet Activation; Recombinant Fusion Proteins; Urokinase-Type Plasminogen Activator | 2015 |
RGD-modified lipid disks as drug carriers for tumor targeted drug delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Erythrocytes; Hemolysis; Humans; Lipids; Male; Melitten; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasms; Oligopeptides; Rats; Rats, Sprague-Dawley; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |